>
Lattice Biologics logo

LBL - Lattice Biologics Share Price

C$0.05 0.0  0.0%

Last Trade - 13/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £3.03m
Enterprise Value £5.40m
Revenue £1.63m
Position in Universe 2280th / 2712
Bullish
Bearish
Unlock LBL Revenue
Momentum
Relative Strength (%)
1m +9.53%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -64.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 2.85 2.74 1.16 2.19 2.46
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 December 2020, LatticeBiologics Ltd revenues decreased 32% to $475K. Net lossincreased from $70K to $269K. Revenues reflect a decreasein demand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsChange in fair value ofwarrants decrease from $4K (income)to $37K (expense), Salaries increase of 13% to $209K(expense), Utilities increase from $11K to $26K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

LBL Revenue Unlock LBL Revenue

Net Income

LBL Net Income Unlock LBL Revenue

Normalised EPS

LBL Normalised EPS Unlock LBL Revenue

PE Ratio Range

LBL PE Ratio Range Unlock LBL Revenue

Dividend Yield Range

LBL Dividend Yield Range Unlock LBL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
LBL EPS Forecasts Unlock LBL Revenue
Profile Summary

Lattice Biologics Ltd. (Lattice) is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company is a precision medicine company in the field of cellular therapies and tissue engineering, with a focus on bone, skin and cartilage regeneration. It produces and distributes multiple allograft tissue products used by surgeons as bone, skin and cartilage tissue void fillers. Its products include Acellular Demineralized Bone Scaffold, Demineralized Bone Matrix putty (DBM Putty), Acellular dermal matrix (ADM) dermal scaffold and Other Products. Its products are used in a range of applications, including enhancing fusion in spine surgery; enhancing breast reconstruction post mastectomy; sports medicine indications, including anterior cruciate ligament repair and promotion of bone growth in foot; promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries.

Directors
Last Annual September 30th, 2020
Last Interim December 31st, 2020
Public Since April 1, 1996
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange TSX Venture Exchange
Shares in Issue 104,605,605
Free Float (0.0%)
Eligible for
ISAs
SIPPs
LBL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for LBL
Upcoming Events for LBL
Frequently Asked Questions for Lattice Biologics
What is the Lattice Biologics share price?

As of 13/04/21, shares in Lattice Biologics are trading at C$0.05, giving the company a market capitalisation of £3.03m. This share price information is delayed by 15 minutes.

How has the Lattice Biologics share price performed this year?

Shares in Lattice Biologics are currently trading at C$0.05 and the price has moved by -52.38% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lattice Biologics price has moved by -65.14% over the past year.

What are the analyst and broker recommendations for Lattice Biologics?

There are no analysts currently covering Lattice Biologics.

When will Lattice Biologics next release its financial results?

Lattice Biologics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Lattice Biologics dividend yield?

Lattice Biologics does not currently pay a dividend.

Does Lattice Biologics pay a dividend?

Lattice Biologics does not currently pay a dividend.

When does Lattice Biologics next pay dividends?

Lattice Biologics does not currently pay a dividend.

How do I buy Lattice Biologics shares?

To buy shares in Lattice Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Lattice Biologics?

Shares in Lattice Biologics are currently trading at C$0.05, giving the company a market capitalisation of £3.03m.

Where are Lattice Biologics shares listed? Where are Lattice Biologics shares listed?

Here are the trading details for Lattice Biologics:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: LBL
What kind of share is Lattice Biologics?

Based on an overall assessment of its quality, value and momentum, Lattice Biologics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Lattice Biologics share price forecast 2021?

We were not able to load any forecast data for Lattice Biologics.

How can I tell whether the Lattice Biologics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lattice Biologics. Over the past six months, the relative strength of its shares against the market has been 22.6%. At the current price of C$0.05, shares in Lattice Biologics are trading at 0.81% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Lattice Biologics PE Ratio?

We were not able to find PE ratio data for Lattice Biologics.

Who are the key directors of Lattice Biologics?

Lattice Biologics's management team is headed by:

Guy Cook - CEO
Kevin Loud - IND
Donna Medina - CFO
Who are the major shareholders of Lattice Biologics?

Here are the top five shareholders of Lattice Biologics based on the size of their shareholding:

Cook (Guy S) Individual Investor
Percentage owned: 26.19% (27.4m shares)
Grenville Strategic Royalty, Corp. Corporation
Percentage owned: 8.81% (9.21m shares)
Loud Kevin R Individual Investor
Percentage owned: 2.55% (2.66m shares)
Farmer (Cheryl) Individual Investor
Percentage owned: 2.32% (2.43m shares)
McInnes (Donald Arthur) Individual Investor
Percentage owned: 1.1% (1.15m shares)
Similar to LBL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.